Equities research analysts expect that Emergent Biosolutions Inc (NYSE:EBS) will announce earnings of $0.96 per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Emergent Biosolutions’ earnings, with estimates ranging from $0.85 to $1.11. Emergent Biosolutions reported earnings per share of $0.13 in the same quarter last year, which would indicate a positive year over year growth rate of 638.5%. The company is expected to issue its next earnings report after the market closes on Thursday, August 2nd.
According to Zacks, analysts expect that Emergent Biosolutions will report full year earnings of $2.35 per share for the current financial year, with EPS estimates ranging from $2.24 to $2.42. For the next financial year, analysts anticipate that the company will report earnings of $2.84 per share, with EPS estimates ranging from $2.38 to $3.21. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.18. Emergent Biosolutions had a net margin of 11.96% and a return on equity of 10.39%. The firm had revenue of $220.20 million during the quarter, compared to analysts’ expectations of $208.94 million. During the same period last year, the business earned $0.13 earnings per share. Emergent Biosolutions’s revenue was up 118.5% compared to the same quarter last year.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock in a transaction dated Monday, July 9th. The shares were sold at an average price of $53.61, for a total transaction of $804,150.00. Following the completion of the sale, the chairman now directly owns 1,539,993 shares in the company, valued at $82,559,024.73. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 15,785 shares of Emergent Biosolutions stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total transaction of $822,556.35. Following the sale, the chief executive officer now owns 197,343 shares of the company’s stock, valued at $10,283,543.73. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,538 shares of company stock valued at $2,798,946. Company insiders own 16.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in EBS. Stratos Wealth Partners LTD. purchased a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $134,000. PNC Financial Services Group Inc. boosted its stake in shares of Emergent Biosolutions by 108.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,482 shares during the period. SG Americas Securities LLC purchased a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $171,000. Financial Gravity Wealth Inc. purchased a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $190,000. Finally, Sei Investments Co. boosted its stake in shares of Emergent Biosolutions by 5,992.1% in the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares during the period. Institutional investors and hedge funds own 82.46% of the company’s stock.
Emergent Biosolutions traded up $0.33, hitting $54.83, during midday trading on Thursday, Marketbeat reports. 199,300 shares of the stock were exchanged, compared to its average volume of 336,359. Emergent Biosolutions has a fifty-two week low of $32.48 and a fifty-two week high of $55.94. The stock has a market cap of $2.71 billion, a P/E ratio of 28.86, a PEG ratio of 1.16 and a beta of 1.20. The company has a current ratio of 5.49, a quick ratio of 3.70 and a debt-to-equity ratio of 0.02.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Featured Article: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.